Emerging as an unconventional yet intriguing approach to the persistent challenges of Long COVID, low-dose nicotine patches are being explored as a potential integrative treatment. The rationale lies in nicotine's ability to compete with SARS-CoV-2 spike proteins at receptor sites, potentially restoring homeostasis. Furthermore, nicotine acts as an agonist of nicotinic acetylcholine receptors (nAChRs), triggering the "cholinergic anti-inflammatory pathway" which could counter the chronic inflammation observed in Long COVID. Anecdotal reports and a small case series suggest that low doses (3.5-7.5 mg/day) may improve debilitating symptoms like fatigue, brain fog, and dyspnea. However, the current evidence base is limited to case reports and patient narratives, as randomized, controlled trials are lacking. While preclinical studies support nicotine's anti-inflammatory properties, potential side effects such as nausea and tachycardia, along with the risk of addiction, necessitate cautious, medically supervised use within an integrative framework that includes foundational treatments like hydration and acupuncture. Nicotine is not viewed as a standalone fix but as a potential adjunct for those unresponsive to standard care, highlighting the ongoing quest for effective solutions to the Long COVID conundrum.